Drugs / LOVOTIBEGLOGENE AUTOTEMCEL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04293185 | Feb 2020 → May 2027 expected | sickle cell disease | Genetix Biotherapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LOVOTIBEGLOGENE AUTOTEMCEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650269 ↗ |
| Known as | bb1111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04293185 ↗ |
| Known as | Lyfgenia | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650269 ↗ |
| Route | Intravenous | “Drug Product is administered by IV infusion” NCT04293185 ↗ |
| Target | HBB | “Hemoglobin beta chain exogenous gene” CHEMBL4650269 ↗ |